| Case 1 |
|
|
|
|
|
|
|
|
|
| Days after onset | 5 | 6* | 9† | 10 | 12‡ | 14 | 19§ | 33 | 99 |
| KL-6 (U/ml) | 1187 | 1304 | 1475 | NA | 1533 | NA | 864 | 396 | 189 |
| SP-D (ng/ml) | NA | 118 | 177 | NA | 129 | NA | 41.5 | NA | NA |
| P/F ratio | 178 | 142 | 122 | 138 | 250 | NA | NA | NA | NA |
| Case 2 |
|
|
|
|
|
|
|
|
|
| Days after onset | 5* | 6† | 7 | 11‡ | 13 | 19§ | 38 | 64 | 78 |
| KL-6 (U/ml) | 1651 | 2003 | 2890 | 5557 | 5282 | NA | 1732 | 1191 | 507 |
| SP-D (ng/ml) | 121 | 212 | 411 | 377 | 291 | NA | 94.7 | NA | 56.1 |
| P/F ratio | 182 | 112 | 95 | 183 | 255 | NA | NA | NA | NA |
| Case 3 |
|
|
|
|
|
|
|
|
|
| Days after onset | 5 | 6* | 7† | 10 | 15† | 17 | 20‡ | 32§ | 59 |
| KL-6 (U/ml) | 296 | 1396 | 2889 | 3763 | 7074 | 6870 | 4204 | 2218 | 684 |
| SP-D (ng/ml) | NA | 122 | 451 | 753 | 626 | 472 | 145 | 105 | 81.9 |
| P/F ratio | NA | 240 | 156 | 77 | 205 | 229 | 287 | NA | NA |